Tuesday, September 20, 2022
H-CYTE, Inc., a medical biosciences company, announced today that the Company has entered into a letter of intent to acquire SkinDisc, a patent pending tissue regeneration technology, that is expected to close within the next 30 days.
Further supports H-CYTE’s vision to build a diverse asset portfolio and transform into a hybrid-biopharmaceutical Company
Early clinical outcomes of SkinDisc application demonstrated significant results relative to current treatment options in wound healing and limb salvaging
250 patients treated with SkinDisc to date
Single application can achieve healing in 4-9 weeks
H-CYTE will submit a De Novo 510(k) pathway request for SkinDisc in the first half of 2023
“The acquisition of SkinDisc represents another significant addition to our portfolio of potentially life-saving technologies under development,” said Michael Yurkowsky, H-CYTE’s Chief Executive Officer. “With the rising prevalence of acute, chronic, and surgical wounds over the last decade, and a total addressable market opportunity of $2 billion, the H-CYTE team is excited to help foster affordable treatments for those in need of wound care and limb salvaging. To best serve those who can benefit from this proprietary technology, the Company plans to work with surgeons, podiatrists, and physicians to treat patients with severe trauma-based wounds and non-healing chronic wounds.”
SkinDisc maintains complete full wound contact and depth filling during the healing process, resulting in rapid growth of the host tissue from an active cellular matrix in a single application. The SkinDisc product has achieved healing in four to nine weeks, compared to current treatment approaches that require weekly applications and can take 12-20 weeks to heal, on average.